Emerging nanotechnologies in cardiovascular medicine

Alessandro Grattoni; John P. Cooke

doi:10.1016/j.nano.2021.102472

Emerging nanotechnologies in cardiovascular medicine

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Article number	102472
Pages (from-to)	102472
Journal	Nanomedicine: Nanotechnology, Biology, and Medicine
Volume	39
DOIs	https://doi.org/10.1016/j.nano.2021.102472
State	Published - Jan 2022

Keywords

Cardiovascular diseases
Drug delivery
Innovative therapeutics
Nanotechnology
Drug Delivery Systems

ASJC Scopus subject areas

Bioengineering
Molecular Medicine
Materials Science(all)
Biomedical Engineering
Medicine (miscellaneous)
Pharmaceutical Science

Access to Document

10.1016/j.nano.2021.102472

Cite this

@article{d3b74da25f5544ed98c7e9c3898249d0,

title = "Emerging nanotechnologies in cardiovascular medicine",

keywords = "Cardiovascular diseases, Drug delivery, Innovative therapeutics, Nanotechnology, Drug Delivery Systems",

author = "Alessandro Grattoni and Cooke, {John P.}",

note = "Funding Information: We express our heartfelt gratitude to the Kostas family for their vision and support and for the establishment of the George and Angelina Kostas Research Center for Cardiovascular Nanomedicine at the Houston Methodist Research Institute. We thank Nicola di Trani for the graphic design. A.G. is supported by funding from National Institutes of Health National Institute of General Medical Sciences (R01GM127558) and J.P.C. has been supported by National Institutes of Health R01s (HL133254 and HL148338), the Cancer Prevention and Research Institute of Texas (CPRIT RP150611), and the George and Angelina Kostas Research Center for Cardiovascular Nanomedicine at Houston Methodist. A.G. is an inventor of patents assigned to Houston Methodist which have been licensed to NanoGland, LLC. J.P.C. is an inventor on patents assigned to Stanford University which have been licensed to ChromeX Bio, a biotechnology startup founded by J.P.C. In addition, J.P.C. is the principal investigator of sponsored research agreements that Houston Methodist has with Avita Medical, Inc. and VGXI, Inc. Funding Information: These technologies exemplify the breath of research efforts in cardiovascular nanomedicine. With the field expanding rapidly, new investments are needed to promote innovative developments. Notably, National Institutes of Health (NIH) funding focused on addressing the burden of CVD is substantially lower compared to other biomedical areas, and is only about half of the funding for cancer. 6 Private organizations, foundations and philanthropy have stepped up to support the efforts in CVD nanomedicine. Among these, the Kostas family has partnered with Houston Methodist and Northeastern University to create a program focused on the development and translation of innovative cardiovascular nanotechnologies. The program currently at its 5th year has provided support for various investigations ranging from nanodevices to RNA therapeutics and fostered multi-institutional and multidisciplinary collaboration among scientists from various institutions, through yearly symposia. This topical issue of Nanomedicine: Nanotechnology Biology and Medicine captures part of the multidisciplinary science and collaborative efforts supported by the Kostas program. The generous philanthropic support is essential for early proof of concept and exploratory studies, leading to mature funding proposals for the NIH, DOD and American Heart Association among others, establishing a model to foster innovative research in the field of Cardiovascular Nanomedicine that can become self-sustaining. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2022",

month = jan,

doi = "10.1016/j.nano.2021.102472",

language = "English (US)",

volume = "39",

pages = "102472",

journal = "Nanomedicine: Nanotechnology, Biology, and Medicine",

issn = "1549-9634",

publisher = "Elsevier",

}

TY - JOUR

T1 - Emerging nanotechnologies in cardiovascular medicine

AU - Grattoni, Alessandro

AU - Cooke, John P.

N1 - Funding Information: We express our heartfelt gratitude to the Kostas family for their vision and support and for the establishment of the George and Angelina Kostas Research Center for Cardiovascular Nanomedicine at the Houston Methodist Research Institute. We thank Nicola di Trani for the graphic design. A.G. is supported by funding from National Institutes of Health National Institute of General Medical Sciences (R01GM127558) and J.P.C. has been supported by National Institutes of Health R01s (HL133254 and HL148338), the Cancer Prevention and Research Institute of Texas (CPRIT RP150611), and the George and Angelina Kostas Research Center for Cardiovascular Nanomedicine at Houston Methodist. A.G. is an inventor of patents assigned to Houston Methodist which have been licensed to NanoGland, LLC. J.P.C. is an inventor on patents assigned to Stanford University which have been licensed to ChromeX Bio, a biotechnology startup founded by J.P.C. In addition, J.P.C. is the principal investigator of sponsored research agreements that Houston Methodist has with Avita Medical, Inc. and VGXI, Inc. Funding Information: These technologies exemplify the breath of research efforts in cardiovascular nanomedicine. With the field expanding rapidly, new investments are needed to promote innovative developments. Notably, National Institutes of Health (NIH) funding focused on addressing the burden of CVD is substantially lower compared to other biomedical areas, and is only about half of the funding for cancer. 6 Private organizations, foundations and philanthropy have stepped up to support the efforts in CVD nanomedicine. Among these, the Kostas family has partnered with Houston Methodist and Northeastern University to create a program focused on the development and translation of innovative cardiovascular nanotechnologies. The program currently at its 5th year has provided support for various investigations ranging from nanodevices to RNA therapeutics and fostered multi-institutional and multidisciplinary collaboration among scientists from various institutions, through yearly symposia. This topical issue of Nanomedicine: Nanotechnology Biology and Medicine captures part of the multidisciplinary science and collaborative efforts supported by the Kostas program. The generous philanthropic support is essential for early proof of concept and exploratory studies, leading to mature funding proposals for the NIH, DOD and American Heart Association among others, establishing a model to foster innovative research in the field of Cardiovascular Nanomedicine that can become self-sustaining. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2022/1

Y1 - 2022/1

KW - Cardiovascular diseases

KW - Drug delivery

KW - Innovative therapeutics

KW - Nanotechnology

KW - Drug Delivery Systems

UR - http://www.scopus.com/inward/record.url?scp=85117951496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85117951496&partnerID=8YFLogxK

U2 - 10.1016/j.nano.2021.102472

DO - 10.1016/j.nano.2021.102472

M3 - Editorial

C2 - 34715052

AN - SCOPUS:85117951496

SN - 1549-9634

VL - 39

SP - 102472

JO - Nanomedicine: Nanotechnology, Biology, and Medicine

JF - Nanomedicine: Nanotechnology, Biology, and Medicine

M1 - 102472

ER -

Emerging nanotechnologies in cardiovascular medicine

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this